CareCloud (NASDAQ:MTBC) and Certara (NASDAQ:CERT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.
Earnings & Valuation
This table compares CareCloud and Certara’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CareCloud||$105.12 million||1.09||-$8.81 million||($1.79)||-4.46|
|Certara||$243.53 million||21.29||-$49.40 million||($0.32)||-106.00|
This is a breakdown of recent recommendations for CareCloud and Certara, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CareCloud presently has a consensus price target of $18.33, suggesting a potential upside of 129.45%. Certara has a consensus price target of $34.50, suggesting a potential upside of 1.71%. Given CareCloud’s stronger consensus rating and higher probable upside, equities research analysts clearly believe CareCloud is more favorable than Certara.
Institutional & Insider Ownership
24.3% of CareCloud shares are held by institutional investors. Comparatively, 30.1% of Certara shares are held by institutional investors. 37.1% of CareCloud shares are held by company insiders. Comparatively, 6.8% of Certara shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares CareCloud and Certara’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
CareCloud beats Certara on 7 of the 13 factors compared between the two stocks.
CareCloud, Inc. brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows, and make better business and care decisions. More than 40,000 providers across the United States count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Services and solutions include revenue cycle management (RCM), practice management (PM), electronic health record (EHR), business intelligence, telehealth, and patient experience management (PXM). CareCloud is headquartered in Somerset, NJ.
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for CareCloud Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareCloud and related companies with MarketBeat.com's FREE daily email newsletter.